Real-time Continuous Glucose Monitoring in Diabetic Cardiothoracic Surgery Patients (MARGE)
Real Time Continuous Glucose Monitoring With Glucoday® as an Assistant for Intensive Insulin Therapy in Diabetic Cardiothoracic Surgery Patients: a Randomized Study Comparing Blood Glucose Measurements Alone or Associated to Continue Glucose Monitoring
Sponsor: Menarini Group
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Menarini Group
- Acute Myeloid Leukemia, in Relapse · Phase PHASE1 · Apr 2021
- Surgical Site Infection · Phase PHASE3 · Oct 2020
- Metastatic Solid Tumors · Phase PHASE1 · Jan 2020
- Tumor Lysis Syndrome · Phase PHASE1/PHASE2 · Jul 2018
- Irritable Bowel Syndrome With Diarrhea · Phase PHASE3 · Nov 2015
More terminations from Menarini Group
Listed as NCT00878891, this NA trial focuses on Diabetes and remains terminated or withdrawn. Sponsored by Menarini Group, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Feb 2018 — Jun 2018 [monthly]
Terminated NA
▶ Show 1 earlier version
-
Jan 2017 — Feb 2018 [monthly]
Terminated NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Menarini Group
- University Hospital, Bordeaux
For direct contact, visit the study record on ClinicalTrials.gov .